DRKS00021659已完成2 期
Phase-IIa randomized, double blind, sham-controlled, parallel group trial on anodal tDCS over the prefrontal cortex on neuropsychological functions and clinical course in patients with ADHD using a home-based stimulation protocol - ADHDStimHome
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 10 Years 至 18 Years（—）
- 性别
- All
入选标准
- •ADHD according to DSM-5 (all subtypes)
- •age 10 to 18
- •participant and their parents or legal guardian are able and willing to give written informed assent and consent
排除标准
- •Birth weight < 2500 gr.
- •Born before the 37th week of pregnancy
- •Past or present neurological diseases or brain surgery
- •Dermatological diseases of the scalp
- •All psychiatric comorbid disorders other than oppositional defiant disorder, conduct disorder, tic disorder, elimination disorders, anxiety disorders, learning disorders
- •Cochlear implants
- •History of craniocerebral injury with loss of consciousness
- •Heart disease
- •Pregnancy
- •Concurrent neurofeedback therapy
- •Concurrent pharmacological treatment of ADHD and also other medication addressing the central nervous system
- •Environment not allowing tDCS session without foreseen disturbances essentially impairing the treatment
- •Expected insufficient compliance towards home-based application*
- •*Self-rated expected compliance and behavioral intention will be measured during telephone screening with short questionnaire
研究者
相似试验
已完成
2 期
Phase-IIa randomized, double-blind, sham-controlled, parallel group trial on anodal tDCS over the left and right tempo-parietal junction in Autism Spectrum DisorderDSM-5 299.0 Autism Spectrum DisorderF84.0F84.1F84.5Childhood autismAtypical autismAsperger syndromeDRKS00014732Goethe University Frankfurt24
已完成
不适用
Phase II, double blind, randomised, controlled study to evaluate immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals Hib-menAC vaccine (Ghana)Vaccination against meningococcal diseaseInfections and InfestationsVaccinationISRCTN35754083GlaxoSmithKline (GSK) Biologicals (Ancillary study - Swiss Tropical Institute) (Belgium)280
进行中（未招募）
不适用
A clinical study to evaluate the efficacy to stop the bleeding and safety of TT-173 applied in the donor site of patients undergoing skin graft.EUCTR2013-002784-25-ESThrombotargets Europe
进行中（未招募）
不适用
A phase II, randomized, double-blind, controlled study to evaluate the immune responses, safety and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis who have relapsed despite anti-TNFa biological therapyMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2009-012041-35-BEeovacs SA48
进行中（未招募）
不适用
A phase II, randomized, double-blind, controlled study to evaluate the immune responses, safety and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis who have relapsed despite anti-TNFa biological therapyMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2009-012041-35-BGeovacs SA48